Cell Medica Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cell Medica Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0480
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cell Medica Ltd (Cell Medica), formerly Immunocode Ltd manufactures and commercializes cellular products. The company uses various technology platforms such as chimeric antigen receptor (CAR), Dominant T cell receptor (TCR), PENTRA Antibody technology and NKT cell platform for manufacturing gene-modified immune cell products. Its pipeline products include CAR-NKT Cells, Dominant TCR and EBV- Targeted T Cells. Cell Medica collaborates with academic institutions to harness human immune system for the treatment of cancer. The company operates in Switzerland, the UK and the US. Cell Medica is headquartered in London, the UK.

Cell Medica Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cell Medica Raises USD73.2 Million in Series C Financing 11
Cell Medica Raises USD78.3 Million in Series B Venture Financing 12
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 13
Cell Medica Raises US$11 Million In Venture Financing 14
Partnerships 15
Cell Medica Enters into Partnership with University College London 15
Licensing Agreements 16
Cell Medica Extends Licensing Agreement with Baylor College of Medicine 16
Acquisition 18
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 18
Cell Medica Acquires Remaining 73% Stake in Delenex Therapeutics 19
Cell Medica Ltd – Key Competitors 20
Cell Medica Ltd – Key Employees 21
Cell Medica Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Jun 13, 2018: Cell Medica Names Julia P. Gregory As Non-Executive Director And Audit Chair 23
Feb 16, 2018: Cell Medica Appoints Kevin S. Boyle As CFO 24
Dec 07, 2017: Cell Medica Announces Appointment of Industry Leader Dr Annalisa Jenkins as Chair 25
Sep 18, 2017: Cell Medica Appoints CSO to Accelerate R&D for CAR and TCR Programmes 26
Product Approvals 27
Feb 21, 2017: Lead cancer immunotherapy candidate receives FDA fast track designation 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Cell Medica Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Medica Raises USD73.2 Million in Series C Financing 11
Cell Medica Raises USD78.3 Million in Series B Venture Financing 12
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 13
Cell Medica Raises US$11 Million In Venture Financing 14
Cell Medica Enters into Partnership with University College London 15
Cell Medica Extends Licensing Agreement with Baylor College of Medicine 16
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 18
Cell Medica Acquires Remaining 73% Stake in Delenex Therapeutics 19
Cell Medica Ltd, Key Competitors 20
Cell Medica Ltd, Key Employees 21
Cell Medica Ltd, Other Locations 22
Cell Medica Ltd, Subsidiaries 22

List of Figures
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cell Medica Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Agappe Diagnostics Ltd-医療機器分野:企業M&A・提携分析
    Summary Agappe Diagnostics Ltd (Agappe) is an in-vitro diagnostic company that offers biochemistry products. The company offers biochemistry, immunochemistry, serology, coagulation, hematology, system reagents, controls and calibrators; point of care, urinalysis and auxiliary products. Its biochemis …
  • ITOCHU Corporation:企業の戦略・SWOT・財務情報
    ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report Summary ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Rafako SA (RFK):企業の財務・戦略的SWOT分析
    Rafako SA (RFK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Sirti SpA:企業の戦略的SWOT分析
    Sirti SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Ambu AS (AMBU B):製品パイプライン分析
    Summary Ambu A/S (Ambu) is a medical device company with a focus on anesthesia, patient monitoring and diagnostics and emergency care markets. It manufactures and markets life supporting devices, catering to hospitals, clinics, sleep laboratories and rescue services. The major products of the compan …
  • Moldex-Metric Inc:企業の戦略的SWOT分析
    Moldex-Metric Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Nisshinbo Holdings Inc. (3105):企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc. (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • AstraZeneca KK-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca KK (AstraZeneca), a subsidiary of AstraZeneca Plc is a drug company that provides prescription medicines. The company offers products such as akoreto, arimidex, iressa, inderal, casodex, crestor, and other tablets. It offers products for oncology, cardiovascular and metabolic dis …
  • Galp Energia SGPS SA (GALP):石油・ガス:M&Aディール及び事業提携情報
    Summary Galp Energia SGPS SA (Galp) is an integrated energy company. It explores for, develops and produces crude oil and natural gas, refines crude oil, and markets refined petroleum products. The company also conducts power generation, produces biodiesel and trades gas. It imports, transports and …
  • Spark Therapeutics Inc (ONCE):企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Votorantim SA:企業の戦略的SWOT分析
    Votorantim SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Yiaco Medical Co:企業の戦略的SWOT分析
    Yiaco Medical Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Celgene Corp (CELG):製薬・医療:M&Aディール及び事業提携情報
    Summary Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaz …
  • Alios BioPharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Alios BioPharma Inc (Alios BioPharma), a subsidiary of Janssen Pharmaceuticals Inc is a biopharmaceutical company that discovers and develops novel therapies for treatment of viral diseases. The company offers drugs for the treatment of viral infections such as respiratory syncytial virus, i …
  • Hertz Global Holdings Inc:戦略・SWOT・企業財務分析
    Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Hertz Global Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Power Grid Corporation of India Ltd (POWERGRID EQ):企業の財務・戦略的SWOT分析
    Power Grid Corporation of India Ltd (POWERGRID EQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Eneco Holding NV-エネルギー分野:企業M&A・提携分析
    Summary Eneco Holding N.V. (Eneco) is an integrated energy company. It produces, trades, transmits and supplies gas, electricity and heat. Eneco undertakes the sale, rental, installation, and maintenance of heating and hot water equipment; and maintenance of the electricity, gas and district heat ne …
  • Reckitt Benckiser Group Plc (RB.):企業の財務・戦略的SWOT分析
    Reckitt Benckiser Group Plc (RB.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Lophius Biosciences GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Baumot Group AG (TINC):企業の財務・戦略的SWOT分析
    Baumot Group AG (TINC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆